Quick Takeaways:
- Boehringer Ingelheim has acquired Swiss biotech Evax AG, strengthening its equine health portfolio with therapeutic vaccine technology targeting significant unmet needs, particularly allergic skin diseases in horses.
- Founded at the University of Zurich, Evax has developed virus-like particle-based therapeutic vaccines designed to stimulate neutralizing antibodies against underlying disease drivers. The approach could offer longer-lasting treatment and greater convenience than current options.
- The acquisition builds on Boehringer Ingelheim’s strategy to advance therapeutic vaccines, following its collaboration and acquisition of Saiba Animal Health in 2024. Financial terms were not disclosed.
Why It Matters?
Boehringer Ingelheim’s purchase of Evax gives it a promising new way to treat common horse allergies with longer‑lasting vaccines instead of short‑term symptom relief, which could mean fewer vet visits and better outcomes for owners. If the approach works as hoped, it could open a new category of horse allergy treatments, help Boehringer stand out in a crowded animal‑health market, and encourage more investment in similar “vaccine‑style” therapies for pets and livestock.
Source: Globenewswire
